Accessibility Menu
Climb Bio logo

Climb Bio(NASDAQ) CLYM

Current Price$12.87
Market Cap$730.68MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-20%
5 YearN/A
1 Year+762%
1 Month+4%
Climb Bio last closing stock price
MetricPriceDate
Last closeUSD 12.762026-07-23
Climb Bio stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+1.43%USD 12.582026-07-16
1 month+3.74%USD 12.302026-06-23
3 month+39.61%USD 9.142026-04-24
Year to date+219%USD 4.002025-12-31
1 year+762.16%USD 1.482025-07-23
3 year+340%USD 2.902023-07-24
Since inception-19.75%USD 15.902021-08-10

Climb Bio Financials at a Glance

Market Cap

$730.68MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$52.79M

EPS (TTM)

-$0.78

P/E Ratio

-16.38

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$12.87

Volume

291,433.478

Open

$12.89

Previous Close

$12.76

Daily Range

$12.25 - $12.90

52-Week Range

$1.36 - $14.42

Estimated Earnings Date

Aug 11, 2026

CLYM News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Climb Bio

Climb Bio develops medicines for people with autoimmune diseases. Its main drugs aim to reduce harmful immune attacks. These treatments target conditions like lupus and kidney inflammation.

What’s in the Medicine Cabinet?

  • Budoprutug (Anti-CD19 antibody): Experimental drug for autoimmune diseases like lupus and immune-related kidney disorders. 0% of revenue (pre-commercial).
  • CLYM116 (Anti-APRIL antibody): Early-stage drug for kidney inflammation and other immune system diseases. 0% of revenue (pre-commercial).
  • Formulation Innovation: Developing both intravenous (IV) and under-the-skin (subcutaneous) versions for easier patient use.
  • Legacy Program (ETX-123): Paused project for nerve-related disorders; not currently active.

Climbing the Growth Ladder

  • Acquired Tenet Medicines in June 2024 to expand its drug pipeline.
  • Signed exclusive license with Mabworks for CLYM116 in January 2025.
  • Launched Phase 2 trial for budoprutug in kidney disease in November 2025.
  • Started Phase 1 trial for CLYM116 in healthy volunteers in November 2025.
  • Raised $120 million in private placement in June 2024 to fund expansion.

Why Climb Bio Stands Out (Without Climbing Too High)

Climb Bio focuses on B-cell biology, targeting immune cells linked to disease. It holds global rights to its main drugs outside China and oncology. The company outsources manufacturing and clinical trials to keep operations lean.

Five Things You Need to Know

  • No revenue reported for 2023, 2024, or 2025; company is pre-commercial.
  • R&D expenses rose 226% to $46.7 million in 2025 from 2024.
  • Net loss was $59.9 million in 2025, improving from $73.9 million in 2024.
  • Cash and investments totaled $160.7 million as of December 31, 2025.
  • Operating cash burn increased to $54.4 million in 2025 from $15.6 million in 2024.

Bottom Line

Climb Bio has shifted from early research to clinical trials, focusing on immune diseases. The company relies on partnerships and licensing to build its drug pipeline.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

28

CEO

Aoife M. Brennan, MD

Website

www.climbbio.com

Headquarters

Wellesley Hills, MA 19808-1609, US

CLYM Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-31.46%

Return on Capital

-42.16%

Return on Assets

-34.65%

Earnings Yield

-6.11%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$730.68MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

57.26M

Volume

291.43K

Avg. Volume

1.25M

Financials (TTM)

Gross Profit

-$106.00K

Operating Income

-$60.08M

EBITDA

-$52.66M

Operating Cash Flow

-$53.30M

Capital Expenditure

-$186.00K

Free Cash Flow

-$53.49M

Cash & ST Invst.

$109.56M

Total Debt

$479.00K

Climb Bio Performance Analysis

Climb Bio annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Climb Bio sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Climb Bio annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -1.72-13.3%
20232023-12-31USD -1.30-24.3%
20242024-12-31USD -1.5317.9%
20252025-12-31USD -0.88-42.5%
Climb Bio sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3058.1%
Q32025-09-30-46.2%
Q42025-12-31-36.8%
Q12026-03-3123.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$38.00K

N/A

Gross Margin

0.00%

N/A

Market Cap

$730.68MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$25.20M

N/A

Employees

29

N/A

Net Income

-$13.72M

+34.0%

EBITDA

-$13.68M

+34.2%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$109.56M

+11.7%

Total Debt

$479.00K

+1.1%

Accounts Receivable

$0.00

-100.0%

Inventory

$0.00

N/A

Long Term Debt

$216.00K

-32.3%

Short Term Debt

$263.00K

+69.7%

Return on Assets

-34.65%

N/A

Return on Invested Capital

-40.51%

N/A

Free Cash Flow

-$14.38M

+6.8%

Operating Cash Flow

-$14.38M

+6.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
TTRXTurn Therapeutics Inc.
$8.83-6.81%
AGENAgenus Inc.
$5.96-3.72%
ABOSAcumen Pharmaceuticals, Inc.
$2.16-0.46%
ANIXAnixa Biosciences, Inc.
$3.75+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.23-0.07%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$43.93+0.02%
CLFCleveland-Cliffs
$11.86+0.08%
MARAMara Holdings
$12.56-0.02%

Questions About CLYM

What is the current price of Climb Bio?

Climb Bio is trading at $12.87 per share.

What is the 52-week range for Climb Bio?

Over the past 52 weeks, Climb Bio has traded between $1.36 and $14.42.

How much debt does Climb Bio have?

As of the most recent reporting period, Climb Bio reported total debt of $479.00K.

How much cash does Climb Bio have on hand?

Climb Bio reported $8.36M in cash and cash equivalents in its most recent financial results.

What is Climb Bio’s dividend yield?

Climb Bio does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services